Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781417 · ClinicalTrials.gov registry record · NA
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
A NA study of Kidney Disease, sponsored by Atlanta VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00781417 is a NA study of Kidney Disease that has completed, run by Atlanta VA Medical Center. The registered enrollment target is 48 participants, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00781417, a NA study of Kidney Disease, has completed, sponsored by Atlanta VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate whether earlier intervention with vitamin D in stage II/III chronic kidney disease will prevent or delay secondary hyperparathyroidism. Subjects will receive vitamin D or placebo at study entry and will be followed for a period of one year. The hypothesis is that subjects given vitamin D will have lower PTH and higher 25(OH)D after 1 year compared to placebo. Additionally, there will be less subjects who progress into secondary hyperparathyroidism in the vitamin D treated group compared to the placebo treated group.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Vitamin D
Study Locations (1)
Georgia
- Atlanta VAMC - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00781417
The ClinicalTrials.gov registry entry for NCT00781417 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (98% lower). The listed sponsor is Atlanta VA Medical Center, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00781417 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00781417 about?
NCT00781417 is a clinical study titled "Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease". This study will evaluate whether earlier intervention with vitamin D in stage II/III chronic kidney disease will prevent or delay secondary hyperparathyroidism. Subjects will receive vitamin D or placebo at study entry and will be followed for a period of one year. The hypothesis is that subjects gi...
What is the current status of trial NCT00781417?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2008-10. Estimated completion is 2011-12.
What conditions does trial NCT00781417 study?
This clinical trial studies the following conditions: Kidney Disease.
What interventions are being tested in trial NCT00781417?
The interventions under investigation include: Placebo (OTHER), Vitamin D (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00781417?
This trial is sponsored by Atlanta VA Medical Center, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00781417 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
RECRUITING · NA
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
RECRUITING · NA
-
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
COMPLETED · NA
-
Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research
COMPLETED · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.